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Abstract
Background
Tissue advanced glycation end product (AGE) accumulation has been proposed as a
marker of cumulative metabolic stress that can be assessed noninvasively by measurement
of skin autofluorescence (SAF). In persons on haemodialysis, SAF is an independent risk
factor for cardiovascular events (CVEs) and all-cause mortality (ACM), but data at earlier
stages of chronic kidney disease (CKD) are inconclusive. We investigated SAF as a risk fac-
tor for CVEs and ACM in a prospective study of persons with CKD stage 3.
Methods and findings
Participants with estimated glomerular filtration rate (eGFR) 59 to 30 mL/min/1.73 m2 on two
consecutive previous blood tests were recruited from 32 primary care practices across Der-
byshire, United Kingdom between 2008 and 2010. SAF was measured in participants with
CKD stage 3 at baseline, 1, and 5 years using an AGE reader (DiagnOptics). Data on hospi-
tal admissions with CVEs (based on international classification of diseases [ICD]-10 coding)
and deaths were obtained from NHS Digital. Cox proportional hazards models were used to
investigate baseline variables associated with CVEs and ACM. A total of 1,707 of 1,741 par-
ticipants with SAF readings at baseline were included in this analysis: The mean (± SD) age
was 72.9 ± 9.0 years; 1,036 (60.7%) were female, 1,681 (98.5%) were of white ethnicity,
and mean (±SD) eGFR was 53.5 ± 11.9 mL/min/1.73 m2. We observed 319 deaths and 590
CVEs during a mean of 6.0 ± 1.5 and 5.1 ± 2.2 years of observation, respectively. Higher
baseline SAF was an independent risk factor for CVEs (hazard ratio [HR] 1.12 per SD,
95% CI 1.03–1.22, p = 0.01) and ACM (HR 1.16, 95% CI 1.03–1.30, p = 0.01). Additionally,
increase in SAF over 1 year was independently associated with subsequent CVEs (HR 1.11
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per SD, 95% CI 1.00–1.22; p = 0.04) and ACM (HR 1.24, 95% CI 1.09–1.41, p = 0.001). We
relied on ICD-10 codes to identify hospital admissions with CVEs, and there may therefore
have been some misclassification.
Conclusions
We have identified SAF as an independent risk factor for CVE and ACM in persons with
early CKD. These findings suggest that interventions to reduce AGE accumulation, such as
dietary AGE restriction, may reduce cardiovascular risk in CKD, but this requires testing in
prospective randomised trials. Our findings may not be applicable to more ethnically diverse
or younger populations.
Author summary
Why was this study done?
• Advanced glycation end products (AGEs) are chemical compounds that play a role in
health problems associated with aging, diabetes, and heart disease.
• The kidneys play a role in removing AGEs; therefore, people with kidney disease can
develop accumulation of AGEs over time.
• The measurement of skin autofluorescence (SAF) is a noninvasive method to assess
AGE accumulation.
• An important previous study found that people requiring dialysis have high SAF levels
and that these are strong predictors of a higher risk of death from heart disease or any
cause, but SAF has not been as well studied in people with milder forms of kidney dis-
ease who are also at higher risk of heart disease.
What did the researchers do and find?
• A total of 1,707 people with relatively mild chronic kidney disease (CKD, stage 3) and
average age of 73 years were enrolled into this study from 32 primary care practices
across Derbyshire, United Kingdom between 2008 and 2010.
• During an observation period of 5 to 6 years, we found that a higher SAF level at enrol-
ment was associated with a 12% higher risk of having a heart attack, heart failure, or
stroke and a 16% higher risk of death from any cause.
• Additionally, an increase in SAF level over 1 year was associated with a 11% higher risk of
having a heart attack, heart failure, or stroke and a 24% higher risk of death from any cause.
What do these findings mean?
• Higher SAF levels are an independent risk factor for heart attacks, heart failure, stroke,
or death from any cause in people with mild chronic kidney disease, though the risk
seems lower than in people requiring dialysis.
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• We should now explore ways to lower AGE levels in people with kidney disease, which
may include adaptations to reduce the amount of AGEs in the diet.
• Because our study population was predominantly elderly and of white ethnicity, our find-
ings may not be directly applicable to more ethnically diverse or younger populations.
Introduction
Advanced glycation end products (AGEs) are cross-linking compounds that play a role in
the pathogenesis of aging, diabetic microvascular complications, and cardiovascular disease
(CVD). Glycation and oxidation of amino groups on proteins results in AGE formation
through a series of nonenzymatic reactions termed the Maillard reaction. AGEs may also be
generated more rapidly by reactions with α-dicarbonyls that are produced during oxidative
stress [1,2]. Tissue accumulation of AGEs has therefore been proposed as a marker of cumula-
tive ‘metabolic stress’. Exogenous AGEs from food (particularly food cooked at high tempera-
tures) [3] and smoking [4] as well as decreased renal excretion in chronic kidney disease
(CKD) [5] may also contribute to AGE accumulation. Skin autofluorescence (SAF) measure-
ment has been developed as a noninvasive marker of AGE accumulation in the skin and has
been validated using skin biopsy samples [6]. Measurement of SAF can be carried out quickly
and easily using portable equipment and may therefore be useful as a noninvasive measure to
risk-stratify persons with CKD.
CKD is associated with a marked increase in cardiovascular events (CVEs), but risk assess-
ment tools developed in general population studies tend to underestimate this risk [7], in part
because of the importance of nontraditional risk factors. AGE accumulation may be one such
risk factor that was suggested by a landmark paper reporting that higher SAF was a strong and
independent risk factor for cardiovascular and all-cause mortality (ACM) in persons on haemo-
dialysis [6]. We have previously reported that in persons with earlier stage CKD, higher SAF
was associated with multiple risk factors for CVD in a cross-sectional analysis [8] and was a risk
factor for increased ACM in univariable but not fully adjusted multivariable models [9]. After a
longer observation period in the same cohort, we sought to investigate whether SAF is an inde-
pendent risk factor for CVEs and ACM persons with CKD stage 3, cared for in primary care.
Methods
The Renal Risk in Derby (RRID) study is a prospective cohort study of persons with CKD
stage 3 recruited from primary care across Derbyshire. A detailed description of methods has
been published previously [8,10]. The study was conducted according to a prospective protocol
and is reported in keeping with the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guideline (S1 STROBE Checklist). Please see S1 Protocol for the lat-
est version of the study protocol.
Participants
Participants were individually recruited from 32 primary care practices across Derbyshire,
United Kingdom between 2008 and 2010. Participating practices were asked to invite persons
over 18 years of age with CKD stage 3 from CKD registers. Eligible persons were selected
using estimated glomerular filtration rate (eGFR) values calculated using the 4-variable modi-
fication of diet in renal disease (MDRD) equation modified for use with isotope dilution mass
spectrometry (IDMS)-standardised creatinine measurement. Two eGFR readings more than
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90 days apart in the range 30 to 59 mL/min/1.73 m2 were required to be eligible. Those with a
previous renal or other solid organ transplant, with an expected life-expectancy of less than 1
year, or who were unable to attend the baseline visit in person were excluded. A total of 8,280
persons were invited to take part in the study by post; 1,822 persons attended for baseline vis-
its, of whom 1,741 were suitable for recruitment. Baseline SAF measurements were obtained
in 1,707 participants, and these are included in the analysis (Fig 1). Participants gave written
informed consent prior to the baseline assessment. The study was approved by Nottingham
Research Ethics Committee 1 (reference number 08/H0403/16) and is included in the National
Institute for Health Research (NIHR) clinical research portfolio (NIHR Study ID 6632). The
study follows the principles of Good Clinical Practice and the Declaration of Helsinki.
Data collection
Study visits took place at the participants’ primary care practice at baseline, 1, and 5 years.
Prior to each visit, participants completed a background questionnaire covering demographics,
Fig 1. Flow chart showing the numbers of participants involved at each stage of the study. CKD. chronic kidney disease;
KDIGO, kidney disease improving global outcomes; SAF, skin autofluorescence.
https://doi.org/10.1371/journal.pmed.1003163.g001
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medical history, smoking history, and medication history (see S1 Questionnaire for the data
questionnaire). Responses were reviewed during the study visit and clarified as needed. Past
medical history of CVD was defined as participant-reported previous myocardial infarction,
stroke, transient ischaemic attack (TIA), amputation or revascularisation for peripheral vascu-
lar disease, and abdominal aortic aneurysm. Participants provided three consecutive early
morning urine samples, stored in a refrigerator prior to the study visit. Urine samples were
analysed for albumin to creatinine ratio. Blood samples for biochemistry and haematology
were taken from each participant. Participants were asked to avoid eating meat for 12 hours
prior to their study visit to avoid confounding their serum creatinine results.
At each study visit, height and weight were measured. Three blood pressure measurements
that differed by less than 10% were obtained after at least 5 minutes rest using an automatic
oscillometric device (UA-767 Plus 30, A&D Medical). The average of three readings was used
for analysis.
Laboratory methods
Blood and urine samples were analysed at a single clinical laboratory at the Royal Derby Hos-
pital. Creatinine was measured using the Jaffe reaction and was standardised to IDMS meth-
ods. eGFR was calculated using the MDRD equation [11] at the time of recruitment, but
for analysis, this was changed to the more accurate chronic kidney disease epidemiology
(CKD-EPI) equation [12], published after recruitment commenced. Additionally, serum was
analysed for standard electrolytes and bone mineral profile. Urinary albumin was measured
using an immunoturbidimetric assay (‘Tina-quant’, Roche Diagnostics, Mannheim, Germany)
on a Roche Modular system. Urine albumin to creatinine ratio (UACR) was measured on
three urine samples from each participant, and a mean value was used for analysis. Serum
high-sensitivity C reactive protein (CRP) (hsCRP™, Roche Diagnostics, Newhaven, UK) was
measured using a Roche Modular P Analyser (Roche Diagnostics) at The Binding Site Group
laboratories, Birmingham, UK.
SAF
SAF was measured using an AGE reader (DiagnOptics Technologies BV, Groningen, The
Netherlands). The AGE reader provides a noninvasive measure of skin AGE levels that has
been validated using data from skin biopsies. A light source emitting light at a wavelength of
320 to 400 nm excites fluorescent moieties in compounds in the skin to produce fluorescence
at wavelength 420 to 600 nm (peak 440 nm). The output represents the ratio between auto-
fluorescence in the range 420 to 600 nm and excitation light in the range 320 to 400 nm and
is reported in arbitrary units (AU). The AGE reader is not able to obtain valid SAF readings
when the skin reflectivity is lower than 6%. Persons with dark skin colour (Fitzpatrick skin col-
our type V–VI) were therefore excluded from this aspect of the study (n = 17). Technical fail-
ure prevented SAF readings in a further 17 participants. We have previously reported that SAF
readings have good reproducibility and repeatability (coefficient of variation of 7%–8%) [8].
Three SAF measurements were taken from the ventral (anterior) surface of the forearm of
each participant, avoiding any tattoos or heavily pigmented areas of skin, and the average was
used for analysis.
Outcomes
The outcomes of interest for this analysis were fatal and nonfatal CVEs and ACM. Data on all
deaths and hospital admissions from date of recruitment to 31 December 2015 were obtained
from NHS Digital under a data sharing agreement. NHS Digital holds data on all deaths (from
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death certificates) and coding data on all hospital admissions in England and Wales. Three
investigators (AS, RJF, and MWT) independently classified cause of death as cardiovascular or
noncardiovascular. Differences were resolved by discussion. CVEs were defined as any cardio-
vascular death or hospitalisation that included myocardial infarction, stroke, TIA, cardiac fail-
ure, revascularisation, or peripheral vascular disease identified from ICD-10 codes in any of
the diagnoses.
Statistical methods
Data are presented as mean ± SD or median (interquartile range) depending on distribution.
Normally distributed continuous variables were compared across tertiles using ANOVA. Non-
parametrically distributed variables were compared using the Kruskal–Wallis test. Categorical
variables were compared using chi squared tests. Missing data were omitted from analyses.
We constructed multilevel mixed-effects models using the mixed command in Stata 15 to
investigate factors associated with SAF as a repeated measure at baseline, Year 1, and Year 5.
Cox proportional hazards models were constructed to investigate variables associated with
time to death from any cause or time to hospitalisation with a CVE or cardiovascular death.
All variables that evidenced a significant univariable association (p< 0.05) with the outcome
of interest were subsequently entered into multivariable models. Model 1 included demo-
graphic and past medical history variables; Model 2 added blood pressure, body mass index
(BMI), eGFR, and UACR; Model 3 added all remaining laboratory variables including high-
sensitivity C reactive protein (hsCRP). Hazard ratios for continuous variables are expressed
per SD change. To facilitate this, continuous variables that were not normally distributed
(UACR and hsCRP) were logarithmically transformed prior to inclusion in Cox proportional
hazards models.
Analyses were conducted using SPSS version 24 (IBM corporation, NY, USA) and Stata 15
(StataCorp LLC, Texas, USA). p< 0.05 was regarded as statistically significant.
Results
Baseline characteristics
Baseline SAF readings were obtained in 1,707 persons and are included in this analysis (98%
of a total of 1,741 in the RRID cohort). The mean age of those included was 72.9 ± 9.0 years,
1,036 (60.7%) were female, 1,681 (98.5%) were of white ethnicity, mean eGFR was 53.5 ± 11.9
mL/min/1.73 m2. Baseline characteristics (including the number of participants with complete
data) are presented in Table 1 by tertile of SAF. Participants in the highest tertile of SAF were
more likely to be male, either a current or previous smoker, have type 1 or 2 diabetes, and have
a past history of CVD. Additionally, higher age, systolic blood pressure (SBP), UACR, serum
uric acid, and hsCRP were associated with a higher tertile of baseline SAF. Lower diastolic
blood pressure (DBP), eGFR, haemoglobin, serum albumin, and total cholesterol were associ-
ated with higher tertile of baseline SAF.
Change in SAF over time
Among 948 participants who had SAF measured at baseline and Year 5, no change in mean
SAF was observed over time (baseline: 2.6 ± 0.6 AU; Year 1: 2.5 ± 0.5 AU, Year 5: 2.7 ± 0.6 AU;
p = 0.1). Multilevel mixed-effects models showed that greater age, male sex, diabetes, previous
CVD, current or previous smoking, lower eGFR, lower serum albumin, and lower haemoglo-
bin were independently associated with higher SAF in repeated measures over the follow-up
period (Table 2).
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CVEs
We observed 590 CVEs during 5.1 ± 2.2 years of observation, of which 105 were fatal. Kaplan–
Meier analysis showed a progressive increase in CVEs across tertiles of baseline SAF (Fig 2).
Additionally, multivariable Cox proportional hazards analysis identified SAF at baseline as an
independent risk factor for time to first CVE (HR 1.12 per SD increase, 95% CI 1.03–1.22,
p = 0.01) together with age, male sex, history of previous CVD, higher UACR, lower DBP,
lower serum albumin, and higher hsCRP (Table 3). In subgroup analyses, baseline SAF
remained independently associated with nonfatal CVEs (S1 Table) but an association with fatal
CVEs in the univariable analysis and initial multivariable analysis (Model 1) was not main-
tained after full multivariable analysis (S2 Table). In a further subgroup analysis of participants
with no events during the first year, change in SAF over 1 year was independently associated
with CVEs (HR 1.11 per SD increase, 95% CI 1.00–1.22; p = 0.04) though the association with
baseline SAF was attenuated (HR 1.12 per SD increase, 95% CI 1.00–1.27; p = 0.06; S3 Table).
ACM
We observed 319 deaths (ACM) during 6.0 ± 1.5 years of observation. Kaplan–Meier analysis
showed a progressive increase in risk of ACM across tertiles of baseline SAF (Fig 3).
Table 1. Baseline characteristics by tertile of SAF.
Variable Numbera Lowest Tertile (n = 560) Middle Tertile (n = 575) Highest Tertile (n = 572) P value
Baseline SAF (AU) 1,707 2.1 ± 0.2 2.7 ± 0.1 3.4 ± 0.4 <0.001
Baseline age (years) 1,707 70.7 ± 9.9 73.0 ± 8.6 74.9 ± 8.1 <0.001
Female sex 1,707 360 (64.3) 359 (62.4) 317 (55.4) 0.005
Diabetes 1,707 50 (8.9) 82 (14.3) 152 (26.6) <0.001
Previous CVD 1,707 88 (15.7) 127 (22.1) 164 (28.7) <0.001
Smoking status
Current 1,707 18 (3.2) 18 (3.1) 43 (7.5) <0.001
Previous 1,707 242 (43.2) 283 (49.2) 327 (57.2) <0.001
BMI (kg/m2) 1,706 28.7 ± 4.9 29.3 ± 5.3 29.1 ± 5.2 0.2
Systolic BP (mmHg) 1,707 133 ± 18 133 ± 18 136 ± 19 0.006
Diastolic BP (mmHg) 1,707 74 ± 11 73 ± 11 71 ± 11 <0.001
eGFR (mL/min/1.73 m2) 1,707 57.1 ± 11.2 53.6 ± 11.0 49.9 ± 12.2 <0.001
UACR (mg/mmol) 1,704 0.2 (0.0–0.9) 0.3 (0.0–1.3) 0.6 (0.0–3.0) <0.001
Albumin (g/l) 1,704 41.1 ± 2.9 41.0 ± 3.4 40.2 ± 3.1 <0.001
Phosphate (mmol/l) 1,676 1.11 ± 0.17 1.11 ± 0.18 1.11 ± 0.18 0.90
Calcium (mmol/l) 1,696 2.38 ± 0.10 2.37 ± 0.10 2.38 ± 0.10 0.4
Bicarbonate (mmol/l) 1,688 25.6 ± 2.5 25.6 ± 2.7 25.3 ± 2.9 0.06
Urate (umol/l) 1,697 374 ± 88 390 ± 96 387 ± 88 0.005
Total Cholesterol (mmol/l) 1,698 4.9 ± 1.2 4.8 ± 1.2 4.6 ± 1.1 <0.001
HDL Cholesterol (mmol/L) 1,698 1.47 ± 0.43 1.47 ± 0.45 1.42 ± 0.42 0.08
Haemoglobin (g/dl) 1,702 13.5 ± 1.3 13.3 ± 1.4 12.9 ± 1.5 <0.001
hsCRP (mg/L) 1,706 2.06 (1.04–4.02) 2.10 (1.09–4.50) 2.56 (1.30–5.26) 0.001
Data are presented as mean ± SD, number (percentage), or median (interquartile range).
P values for trend across tertiles by ANOVA, Chi squared test, or Kruskal–Wallis test.
aNumber of complete data for each variable.
Abbreviations: AU, arbitrary units; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high
density lipoprotein; hsCRP, high-sensitivity C reactive protein; SAF, skin autofluorescence; UACR, urine albumin to creatinine ratio
https://doi.org/10.1371/journal.pmed.1003163.t001
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Table 2. Multilevel mixed-effects models for associations with SAF as a repeated measure at baseline, Year 1, and Year 5.
Variable Univariable analysis Multivariable analysis (n = 1,668)
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Age 0.01 (0.01–0.02) <0.001 0.01 (0.00–0.01) <0.001
Male sex 0.16 (0.10–0.21) <0.001 0.11 (0.05 to −0.16) <0.001
Diabetes 0.34 (0.28–0.41) <0.001 0.23 (0.16–0.30) <0.001
Previous CVD 0.22 (0.16–0.29) <0.001 0.11 (0.05–0.17) <0.001
Previous smoker 0.15 (0.09–0.20) <0.001 0.10 (0.05–0.15) <0.001
Current smoker 0.28 (0.16–0.40) <0.001 0.41 (0.29–0.52) <0.001
eGFR −001 (−0.02 to −0.01) <0.001 −0.01 (−0.01 to −0.00) <0.001
UACR 0.00 (0.00–0.00) 0.02 −0.00 (−0.00 to 0.00) 0.84
Total cholesterol −0.09 (−0.11 to −0.07) <0.001 −0.02 (−0.04 to −0.00) 0.08
Albumin −0.02 (−0.03 to −0.02) <0.001 −0.01 (−0.02 to −0.00) 0.02
Bicarbonate −0.02 (−0.03 to −0.01) <0.001 −0.01 (−0.02 to 0.00) 0.18
Haemoglobin −0.08 (−0.10 to −0.07) <0.001 −0.06 (−0.08 to −0.04) <0.001
hsCRP 0.00 (0.00–0.01) <0.001 0.00 (−0.00 to 0.00) 0.09
Abbreviations: CVD, cardiovascular disease, eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C reactive protein; SAF, skin autofluorescence; UACR,
urine albumin to creatinine ratio
https://doi.org/10.1371/journal.pmed.1003163.t002
Fig 2. Kaplan–Meier plot showing CVE free survival by tertiles of SAF (dotted line, lowest tertile; dashed line, middle tertile;
solid line, highest tertile; log-rank test: chi-square 41.4; p< 0.001). CVE, cardiovascular event; SAF, skin autofluorescence.
https://doi.org/10.1371/journal.pmed.1003163.g002
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Additionally, multivariable analysis identified SAF at baseline as an independent risk factor for
ACM (HR 1.16 per SD increase, 95% CI 1.03–1.30, p = 0.01) together with age, male sex, his-
tory of previous CVD, lower eGFR, and higher hsCRP (Table 4). In subgroup analyses, base-
line SAF remained independently associated with noncardiovascular deaths (S4 Table), but
an association with cardiovascular deaths in the univariable analysis and initial multivariable
analysis (Model 1) was not maintained after full multivariable analysis (S2 Table). In a further
subgroup analysis of participants who survived beyond the first year, change in SAF over 1
year was independently associated with ACM (HR 1.24 per SD increase, 95% CI 1.09–1.41,
p = 0.001) in addition to baseline SAF (HR 1.25 per SD increase, 95% CI 1.07–1.45; p = 0.005;
S5 Table).
Sensitivity analysis
Sensitivity analyses were undertaken after excluding participants with diabetes to test whether
associations with SAF could be attributable to higher SAF values in persons with diabetes.
Among 1,423 participants without diabetes, higher SAF remained independently associated
with time to first CVE (HR 1.13 per SD increase; 95% CI 1.02–1.25; p = 0.02; S6 Table), but the
association with ACM was no longer statistically significant (HR 1.08 per SD increase, 95% CI
0.95–1.24; p = 0.3) in fully adjusted models (S7 Table).
Discussion
We have identified higher SAF as an independent risk factor for CVEs and ACM in a cohort
of persons with predominantly early CKD stage 3. Additionally, an increase in SAF over 1 year
Table 3. Cox proportional hazards model showing variables associated with time to first CVE.
Variable Univariable Model 1 (n = 1,707) Model 2 (n = 1,703) Model 3 (n = 1,675)
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
SAF 1.37 (1.27–1.48) <0.001 1.20 (1.10–1.30) <0.001 1.15 (1.06–1.25) 0.001 1.12 (1.03–1.22) 0.01
Age 1.54 (1.41–1.69) <0.001 1.39 (1.26–1.53) <0.001 1.31 (1.18–1.46) <0.001 1.31 (1.17–1.45) <0.001
Male sex 1.79 (1.52–2.11) <0.001 1.47 (1.24–1.74) <0.001 1.45 (1.22–1.73) <0.001 1.51 (1.23–1.86) <0.001
Diabetes 1.33 (1.08–1.62) 0.006 1.09 (0.89–1.35) 0.4 0.94 (0.76–1.17) 0.6 0.95 (0.76–1.20) 0.6
Previous CVD 2.51 (2.12–2.97) <0.001 1.94 (1.63–2.31) <0.001 1.90 (1.59–2.27) <0.001 1.94 (1.62–2.33) <0.001
Hypertension 1.76 (1.31–2.36) <0.001 1.28 (0.95–1.73) 0.1 1.14 (0.84–1.56) 0.4 1.23 (0.90–1.69) 0.2
Ever smoked 1.44 (1.22–1.69) <0.001 1.14 (0.96–1.35) 0.2 1.10 (0.92–1.31) 0.3 1.08 (0.91–1.29) 0.4
Systolic BP 1.06 (0.98–1.15) 0.2 1.01 (0.91–1.11) 0.9 1.01 (0.92–1.12) 0.8
Diastolic BP 0.79 (0.73–0.86) <0.001 0.89 (0.80–0.98) 0.02 0.89 (0.80–0.99) 0.03
BMI 1.03 (0.95–1.12) 0.5 1.12 (1.02–1.22) 0.01 1.08 (0.99–1.19) 0.09
eGFR 0.69 (0.63–0.75) <0.001 0.88 (0.80–0.97) 0.009 0.93 (0.84–1.04) 0.2
UACR (log) 1.31 (1.20–1.43) <0.001 1.15 (1.05–1.26) 0.002 1.12 (1.02–1.22) 0.02
Albumin 0.80 (0.74–0.86) <0.001 0.89 (0.81–0.96) 0.005
Uric acid 1.23 (1.14–1.34) <0.001 1.02 (0.92–1.12) 0.7
Total cholesterol 0.80 (0.73–0.87) <0.001 1.05 (0.95–1.15) 0.3
HDL cholesterol 0.79 (0.72–0.87) <0.001 0.91 (0.82–1.01) 0.07
Haemoglobin 0.84 (0.77–0.91) <0.001 0.94 (0.86–1.03) 0.2
hsCRP (log) 1.25 (1.15–1.35) <0.001 - 1.11 (1.02–1.21) 0.02
Hazard ratios for continuous variables are expressed per SD change.
Abbreviations: BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; CVE, cardiovascular event; eGFR, estimated glomerular filtration rate; HDL,
high density lipoprotein; HR, hazard ratio; hsCRP, high-sensitivity C reactive protein; SAF, skin autofluorescence; UACR, urine albumin to creatinine ratio
https://doi.org/10.1371/journal.pmed.1003163.t003
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was an independent predictor of CVEs and ACM. Our observations extend the findings of pre-
vious studies that identified higher SAF as an independent risk factor for cardiovascular mor-
tality and ACM in persons receiving haemodialysis [6] by showing that this association is also
present at a much earlier stage of CKD. Sensitivity analyses confirmed that the association
with CVEs persisted when persons with diabetes were excluded, though the association with
ACM was no longer significant.
Several individual studies and a meta-analysis have confirmed that higher SAF is a strong
and independent predictor of cardiovascular mortality and ACM in persons receiving haemo-
dialysis (HD). The first comprehensive study to report this association found that each 1 AU
increase in baseline SAF was independently associated with an odds ratio (OR) of 3.9 (95% CI
1.9–8.1) for ACM and an OR of 6.8 (95% CI 2.6–17.5) for cardiovascular mortality in a cohort
of 109 persons on HD after 3 years of follow-up [6]. A meta-analysis that included 10 studies
of persons with diabetes (n = 2), peripheral arterial disease (n = 1), and CKD (n = 7), reported
that higher SAF was associated with an increased risk of cardiovascular mortality and ACM.
In a subgroup analysis that included only studies of HD patients, higher SAF was similarly
associated with higher risk of cardiovascular mortality (HR 1.97; 95% CI 1.11–3.49) and ACM
(HR 2.37; 95% CI 1.72–3.26) [13]. Additionally, in one study, an increase in SAF over 1 year
was independently associated with higher subsequent mortality on HD [14]. Similar observa-
tions have been reported in persons performing peritoneal dialysis (PD), though a relatively
small number of participants precluded multivariable analysis [15,16]. In a mixed study
Fig 3. Kaplan–Meier plot showing survival by tertiles of SAF (dotted line, lowest tertile; dashed line, middle tertile; solid line,
highest tertile; log-rank test: chi-square 42.5; p< 0.001). SAF, skin autofluorescence.
https://doi.org/10.1371/journal.pmed.1003163.g003
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population of persons with predialysis CKD stage 5 or receiving HD and PD, higher SAF pre-
dicted ACM in a multivariable analysis that included traditional Framingham risk factors but
was no longer significant after the addition of previous CVD, C reactive protein (CRP), and
serum albumin [17]. In persons with earlier stages of CKD, higher SAF has been associated
with several aspects of CVD including coronary artery calcification [18], subclinical athero-
sclerosis [19], and arterial stiffness [8]. Similarly, previous analyses from the RRID cohort
reported independent associations between higher SAF and multiple cardiovascular risk fac-
tors including older age, male sex, diabetes, past history of CVD, smoking status, lower eGFR,
higher urine protein to creatinine ratio, lower haemoglobin, and lower socioeconomic status
[8]. An analysis of deaths after a mean of 3.6 years of observation found that higher SAF was
a predictor of ACM in univariable as well as age and sex adjusted models but not in a fully
adjusted model [9]. With the benefit of a longer observation period resulting in a greater num-
ber of outcome events, we have confirmed that higher baseline SAF and increase in SAF over 1
year are independent predictors of CVEs and ACM in early stage CKD after adjustment for
traditional risk factors and, importantly, also CRP. One study has reported that higher SAF
predicted incident diabetes, CVEs, and ACM in a large cohort enrolled from the general popu-
lation [20].
Several mechanisms may account for the association between higher SAF and CVEs as
well as mortality. AGEs form cross-links between collagen and elastin molecules in arterial
walls resulting in arterial stiffness that has been strongly implicated in the pathogenesis of
CVD related to CKD [1]. Additionally, AGEs bind to a specific receptor (receptor for
AGE [RAGE]) and provoke endothelial dysfunction [21] as well as inflammation [22] that
likely contribute to the pathogenesis of atherosclerosis. Furthermore, in murine models,
Table 4. Cox proportional hazards model showing variables associated with time to death from any cause.
Variable Univariable Model 1 (n = 1,707) Model 2 (n = 1,703) Model 3 (n = 1,675)
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
SAF 1.51 (1.37–1.67) <0.001 1.26 (1.13–1.40) <0.001 1.19 (1.06–1.33) 0.003 1.16 (1.03–1.30) 0.01
Age 2.46 (2.14–2.83) <0.001 2.26 (1.96–2.61) <0.001 1.93 (1.65–2.25) <0.001 1.90 (1.62–2.23) <0.001
Male sex 2.02 (1.62–2.51) <0.001 1.51 (1.20–1.90) 0.001 1.35 (1.07–1.72) 0.01 1.37 (1.03–1.81) 0.03
Diabetes 1.45 (1.11–1.89) 0.007 1.18 (0.90–1.55) 0.2 1.09 (0.82–1.45) 0.6 1.08 (0.80–1.46) 0.6
Previous CVD 2.38 (1.90–2.98) <0.001 1.66 (1.32–2.10) <0.001 1.64 (1.30–2.08) <0.001 1.62 (1.27–2.06) <0.001
Hypertension 1.66 (1.11–2.47) 0.014 1.00 (0.67–1.51) 1.0 0.87 (0.57–1.33) 0.5 0.94 (0.61–1.46) 0.8
Ever smoked 1.71 (1.36–2.16) <0.001 1.33 (1.05–1.70) 0.02 1.27 (0.99–1.62) 0.06 1.21 (0.94–1.54) 0.1
Systolic BP 1.12 (1.00–1.25) 0.05 1.01 (0.89–1.15) 0.9 1.03 (0.90–1.18) 0.7
Diastolic BP 0.75 (0.67–0.84) <0.001 0.93 (0.81–1.07) 0.3 0.93 (0.80–1.07) 0.3
BMI 0.85 (0.75–0.95) 0.005 0.94 (0.83–1.07) 0.3 0.91 (0.79–1.04) 0.2
eGFR 0.52 (0.46–0.58) <0.001 0.73 (0.64–0.84) <0.001 0.77 (0.66–0.89) 0.001
UACR (log) 1.47 (1.30–1.66) <0.001 1.19 (1.05–1.35) 0.007 1.12 (0.98–1.28) 0.09
Albumin 0.78 (0.71–0.85) <0.001 0.92 (0.81–1.04) 0.2
Uric acid 1.30 (1.17–1.45) <0.001 1.02 (0.90–1.16) 0.7
Total cholesterol 0.71 (0.63–0.80) <0.001 0.94 (0.82–1.09) 0.4
HDL cholesterol 0.81 (0.71–0.91) 0.001 0.98 (0.86–1.13) 0.8
Haemoglobin 0.76 (0.68–0.85) <0.001 0.98 (0.87–1.11) 0.8
hsCRP (log) 1.41 (1.27–1.56) <0.001 1.25 (1.12–1.40) <0.001
Hazard ratios for continuous variables are expressed per SD change.
Abbreviations: BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; HR,
hazard ratio; hsCRP, high-sensitivity C reactive protein; SAF, skin autofluorescence; UACR, urine albumin to creatinine ratio
https://doi.org/10.1371/journal.pmed.1003163.t004
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atherosclerosis was significantly ameliorated by blockade of RAGE or administration of solu-
ble RAGE [23], suggesting reduced activation of RAGE may prevent atherosclerosis and
reduce cardiovascular risk.
Few studies have described longitudinal changes in SAF over time. We found no significant
changes in mean SAF over 5 years, but as higher SAF associates with mortality, those with
higher baseline levels or a greater increase over time would have been less likely to survive to
year 5 follow-up. In multilevel mixed-effects models, we identified multiple baseline variables
that were independently associated with higher SAF in repeated measures over the follow-up
period including greater age, male sex, diabetes, current or past history of smoking, previous
CVD, lower eGFR, lower serum albumin, and lower haemoglobin. These findings are consis-
tent with previous cross-sectional studies that have reported associations between higher SAF
and lower GFR as well as other cardiovascular risk factors [8]. Other factors, such as dietary
intake and cooking methods, have been associated with changes in AGE levels but were not
captured in this population.
SAF is of particular interest as a risk marker, because it is potentially modifiable. A cross-
sectional analysis showed lower SAF levels in renal transplant recipients compared to those on
either PD or HD, implying that SAF decreases with improved GFR after transplantation [24].
This was confirmed by observation of a decrease in SAF levels in a small number of renal trans-
plant recipients, compared with SAF values recorded while they were on dialysis [24]. AGEs
may also enter the body from exogenous sources, including smoking and diet, particularly
foods cooked at high temperatures. Dietary changes may therefore also reduce tissue AGE
accumulation and SAF measurements. This notion is supported by a cross-sectional analysis
of the impact of diet on SAF in persons on HD which reported lower SAF in 27 of 332 partici-
pants who followed a vegetarian diet, predicted to be low in AGE content [25]. Furthermore,
small randomised studies in persons on HD (n = 18) [26] and PD (n = 20) [27] have reported
a reduction in serum AGE levels in response to a low AGE diet, though SAF was not assessed.
The hypothesis that dietary AGE restriction is effective to reduce CVEs and improve survival
in persons with CKD requires testing in prospective randomised controlled trials.
Sensitivity analyses showed that the association between SAF and CVEs remained present
when persons with diabetes were excluded, confirming that elevated SAF was not simply a sur-
rogate for diabetes. Additionally in the multivariable analyses, SAF was an independent predic-
tor of CVEs and ACM but diabetes was not (Tables 3 and 4).
Limitations of this study include a predominantly white and elderly study population. Addi-
tionally, the AGE reader is limited in its applicability to persons of African and African-Carib-
bean ethnicity because of reduced levels of reflected light from darker skin. Our findings may
therefore not be applicable to more ethnically diverse or younger populations. Additionally,
1,822 out of 8,280 persons who were invited agreed to participate in the study, potentially
resulting in some selection bias. Nevertheless, the baseline data indicate that our study popula-
tion was representative of patients with CKD followed up in primary care in England [28].
We relied on ICD-10 codes to identify hospital admissions with CVE, and there may therefore
have been some misclassification. Nevertheless, coding practice is well-established and rigorous
in the NHS, and similar coding data have been used in other large cohort studies including the
UK Biobank [29]. At very least, each code represents a hospital admission. Office blood pressure
was recorded, but ambulatory blood pressure was not assessed. We were therefore unable to
assess the impact of masked hypertension or nocturnal dipping on outcomes. The observed
association of lower cholesterol with CVEs and ACM may have resulted from reverse causality
due to more persons with CVD receiving lipid lowering therapy. Unfortunately, data on lipid
lowering therapy were not available for inclusion in the analysis. Because this was an observa-
tional study, the observed associations should not be interpreted as indicating a causal link
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between SAF and CVEs or ACM. Prospective trials of interventions that reduce SAF will be
required to explore this. Finally, the subgroup analyses should be interpreted with consideration
of the fact that in each case a lower number of events resulted in reduced statistical power.
Conclusions
This analysis showed that higher SAF was independently associated with an increased risk of
CVEs and ACM in the largest cohort of persons with CKD stage 3 studied to date. An addi-
tional novel finding was that change in SAF over 1 year was associated with an increased risk
of CVEs and ACM. These findings support the hypothesis that interventions aimed at reduc-
ing AGE levels would be potentially beneficial in improving cardiovascular outcomes and sur-
vival in persons with CKD, but this should now be tested in prospective randomised trials.
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